{
    "Trade/Device Name(s)": [
        "cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test",
        "cobas\u00ae liat SARS-CoV-2 & Influenza A/B v2"
    ],
    "Submitter Information": "Roche Molecular Systems, Inc.",
    "510(k) Number": "K243400",
    "Predicate Device Reference 510(k) Number(s)": [
        "K241240"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QOF"
    ],
    "Summary Letter Date": "October 30, 2024",
    "Summary Letter Received Date": "October 31, 2024",
    "Submission Date": "April 14, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-CoV-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA",
        "Influenza A RNA",
        "Influenza B RNA"
    ],
    "Specimen Type(s)": [
        "Anterior nasal swab",
        "Nasopharyngeal swab"
    ],
    "Specimen Container(s)": [
        "Copan FLOQSwabs with UTM",
        "BD UVT with flocked swabs",
        "Sterile flocked swabs with synthetic tip with other viral transport media (VTM) - Remel MM4RT, M4, M5, M6",
        "0.9% Saline"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas\u00ae liat System",
        "cobas\u00ae liat analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Reverse transcription PCR (RT-PCR)",
        "Multiplex PCR"
    ],
    "Methodologies": [
        "Nucleic acid amplification",
        "Multiplex real-time RT-PCR",
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Analyzer",
        "System",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test, a rapid automated multiplex RT-PCR assay for qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B RNA in respiratory specimens",
    "Indications for Use Summary": "Simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus RNA in anterior nasal and nasopharyngeal swabs from individuals with respiratory infection symptoms to aid in differential diagnosis; not intended to detect influenza C virus.",
    "fda_folder": "Microbiology"
}